Biosynex finalizes the sale of its molecular biology business

Biosynex, a company listed on Euronext Growth, has officially completed the sale of its molecular biology business. This decision follows approval from the bankruptcy judge and the agreement of the secured creditors. The final contract was signed on June 10, 2026. This event is part of a restructuring aimed at refocusing its efforts on rapid diagnostic tests (RDTs) and therapeutic drug monitoring.

The company had previously faced the liquidation of its subsidiary Avalun. In May 2026, an offer to acquire Avalun's movable assets was accepted. At the same time, Jérôme Silvestre resigned from his position as auditor for personal reasons, effective May 30, 2026.